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Abstract Neuroprotective and/or neuroregenerative activi-
ty of FK506, its derivatives, and to a lesser extent cyclo-
sporin A (CsA) in animal models of neurodegenerative
diseases of different etiology have been reported. Here, we
verified a hypothesis that the most likely mechanism of their
neuroprotective action is inhibition of the early steps of
inflammatory activation of microglia by interference with
mitogen-activated protein kinase (MAPK) signaling. The
effect of immunosuppressants on lipopolysaccharide
(LPS)-induced changes in morphology, proliferation, and
motility of rat primary microglial cultures was evaluated.
FK506 and CsA directly inhibited LPS-induced microglia
activation and inflammatory responses. While both drugs
efficiently reduced the expression of iNOS and the re-
lease of nitric oxide, only FK506 strongly inhibited the
expression of Cox-2 and secretion of the mature form of
IL-1β. FK506 strongly reduced LPS-induced activation
of MAPK, and its downstream signaling crucial for in-
flammatory responses. Comparative analysis of global
gene expression in rat ischemic brains and in LPS-
stimulated microglial cultures revealed many genes and
signaling pathways regulated in the same way in both
systems. FK506 treatment blocked a majority of genes
induced by an ischemic insult in the cortex, in particular
inflammatory/innate immunity and apoptosis-related
genes. Microglia-mediated inflammation is considered as
one of the most important components of brain injury
after trauma or stroke; thus, effective and multifaceted
blockade of microglial activation by FK506 has clinical
relevance and potential therapeutic implications.
Keywords CNS inflammation . Microglia activation .
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Introduction
Microgliosis is one of the most important components of
poststroke neuroinflammation which is also accompanied
by astrogliosis, and manifests in local inflammation, infil-
tration of immune cells, and activation of the adaptive
immunity [1]. In response to brain injury or infection, intra-
cellular signaling pathways are activated in microglia,
which turn on inflammatory and antigen-presenting cell
functions. Acute activation of microglia can contribute to
neuronal damage by production of cytotoxic and inflamma-
tion mediators such as nitric oxide, reactive oxygen species,
prostaglandin products, pro-inflammatory cytokines IL-1β,
tumor necrosis alpha (TNF-α), IL-2, IL-6, or by autoim-
mune mechanisms [2, 3]. Clinical and experimental data
showed a detrimental role of inflammatory cytokines in
injured brain, and inhibition of IL-1β and TNF-α activity
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with neutralizing antibodies or soluble receptors decreased
neuronal damage in animal models of stroke [4, 5].
Numerous studies have reported neuroprotective and/or
neuroregenerative activity of immunosuppressant FK506,
its derivatives, and to a lesser extent cyclosporin A (CsA)
in animal models of neurological diseases of different etiol-
ogy: traumatic brain injury, spinal cord injury, optic nerve
crush, antiretroviral toxic neuropathy, rodent models of
Parkinson's disease, and stroke [6–8]. Therapeutic time win-
dow of FK506 is narrow: 2–3 h in the rat middle cerebral
artery occlusion (MCAo) model. In the nonhuman primate
stroke model, drug administration 2 h after the ischemic
insult significantly reduced neurological deficits and infarct
volumes in the cerebral cortex. Administration of FK506 4 h
after the insult showed significant amelioration of neurolog-
ical deficits, suggesting a therapeutic time window for
FK506 comparable with 3–4.5 h reported for a tissue plas-
minogen activator (rt-PA, alteplase) [9]. FK506 exerts mul-
tiple types of action, such as inhibition of apoptotic and
necrotic cell death in cultured neurons, attenuation of
leukocyte accumulation, and attenuation of glia activation
[10, 11]. It suggests the drug's interference with cellular
processes which are common to many neuropathological
conditions, and a mechanistic pathway for its neuroprotec-
tive effect in vivo needs to be explored.
We have previously demonstrated that FK506 adminis-
tered 1 h after transient MCAo reduced microglia activation
as well as hypertrophy of astrocytes in the ischemic penum-
bra, ameliorating brain damage and neurological deficits
[12]. Recently, we performed global gene expression profil-
ing and the functional analysis of the genes affected after
MCAo in rats revealed that the ten significantly overrepre-
sented gene categories include “response to wounding” and
“inflammatory response” [13]. This may represent gene
induction in activated microglia as the early expression of
inflammatory cytokines in the ischemic brain has been
demonstrated predominantly in microglia [12]. Thus, we
hypothesized that FK506 may act by blocking initiation of
microglial inflammatory responses.
In the present study, we demonstrate that FK506 is a
potent inhibitor of microglial activation and production of
inflammation mediators. It likely interferes with activation
of mitogen-activated protein kinases (MAPK) and nuclear
factor kappa B (NFκB) signaling pathways, crucial for
regulation of inflammatory gene expression. We identified
an inflammatory gene signature common for lipopolysac-
charide (LPS)-stimulated microglial cultures and ischemic
brain, and demonstrated the inhibitory effect of FK506 on
the expression of numerous genes related to inflammatory
response and cell death in a rat model of stroke. We postu-
late that pharmacological intervention with FK506 may be a
good therapeutic strategy targeting the inflammatory com-
ponent of stroke.
Methods
Cell culture and treatment
Primary cultures of rat microglia were prepared as described
[14]. Briefly, cells were isolated from cerebral cortices and
plated at the density of 3×105 cells/cm2 in culture me-
dium (DMEM/Glutamax/high glucose, Gibco, 10 % FBS,
100 U/mL penicillin, and 0.1 mg/mL streptomycin) on
poly-L-lysine-coated culture flasks. After 2 weeks of culture,
the loosely adherent microglial cells were recovered from
confluent glial cultures by a mild shaking and centrifugation.
Cells were suspended in the culture medium and plated at
density of 3×105 cells/cm2 onto 24-well plates or 60-mm
dishes. Nonadherent cells were removed after 30 min by
changing the medium. Adherent cells (>96 % positive for
isolectin B4) were incubated for 48 h. Cells were stimulated
with 100 ng/mL LPS from Salmonella enteritidis (Sigma,
Germany). Compounds were added 30 min before LPS stim-
ulation. FK506 (LC Laboratories, Woburn, MA, USA) was
diluted in ethanol; control cells received an equal amount of
ethanol. Cyclosporin A (Sandimmune, Novartis, Basel, Swit-
zerland) was diluted in a culture medium.
Immunocytochemistry
For immunocytochemistry, cells were fixed with 4 %
paraformaldehyde at indicated time points after treatment.
Next, cells were incubated with fluorescein isothiocyanate
(FITC)-conjugated isolectin B4 from Bandeiraea simplici-
folia (10 μg/mL, Sigma, Germany) for 4 h at room temper-
ature and counterstained with DAPI (4′,6-diamidino-2-
phenylindole, Sigma, Germany, 10 μg/mL). The effects of
the compounds were monitored by fluorescent microscopy
(450–490 nm). Ten randomly distributed visual fields were
captured for each experimental condition used in three in-
dependent experiments. Cell body area was measured using
ImageJ software (NIH, http://rsb.info.nih.gov/ij/).
Proliferation and cell motility assays
Microglial proliferation was determined by BrdU incorpo-
ration assay in cell cultures exposed to various treatments
(untreated, 100 ng/mL LPS alone, or with immunosuppres-
sant). After 18 h, BrdU (10 μM) was added to the culture
medium for 6 h, and subsequently, cells were fixed, and the
level of BrdU incorporation was estimated according to the
manufacturer’s protocol (Roche, Mannheim, Germany).
For motility assay, cells were plated on a 35-mm Petri
dish, and the cultures were gently scratched using a 100-μl
pipette tip. After washing with phosphate-buffered saline
(PBS), cells were left untreated or were exposed for 6 h to
LPS alone or in combination with 5 μM FK506 or CsA. The
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cells were fixed and cell nuclei were stained with DAPI.
Cells from more than three representative fields for every
treatment were counted using ImageJ software.
Evaluation of IL-1β and nitric oxide production
Microglia were stimulated with LPS alone or in combination
with immunosuppressants. Twenty-four hours after stimula-
tion, the culture media were collected, centrifuged at 500×g
for 10 min, and the supernatants were used for determination
of NO and cytokine production. NO production was assessed
with the NO release assay (ActiveMotif, Rixensart, Belgium).
IL-1β production was measured by ELISA using rat-specific
antibody pairs and rat protein standards in accordance with the
manufacturer's instructions (R&D Systems, Wiesbaden,
Germany). Cytokine levels were calculated as nanograms
per milliliter and expressed as a percentage of the IL-1β
release in control cultures.
Protein isolation, electrophoresis, and detection
Whole-cell protein extracts were separated on SDS–PAGE
and transferred onto a nitrocellulose membrane (Amersham
Biosciences, Germany). Antibodies recognizing phosphory-
lated forms of p38, p44/42 MAP kinase (ERK1/2), JNK,
MAPKAP-2, c-Jun, and IκB as well as Cox-2 (1:1,000)
were purchased from Cell Signaling Technology (Beverly,
MA, USA), inducible NO synthase (iNOS; diluted 1:2,000)
was from BD Biosciences (Bedford, MA, USA) and IL-1β
(diluted 1:1,000) from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Immunocomplexes were visualized by
using ECL (Amersham). To verify equal amounts of protein
loading, the membranes were reprobed with anti-β-Actin
antibody (diluted 1:2,000, from Oncogene Research Prod-
ucts, MA, USA).
Transient middle cerebral artery occlusion and RNA
extraction
MCAo was induced for 90 min with the intraluminal fila-
ment method as described [12, 13]. The procedure resulted
in ischemic damage in the frontoparietal somatosensory
cortex, striatum, and other areas such as hypothalamus,
corresponding to the territory supported by the middle cere-
bral artery (MCA). FK506 (Tacrolimus, Fujisawa, UK) was
administrated intravenously at 1 mg/kg body weight 60 min
after MCAo. FK506 significantly reduced tissue damage in
the cerebral cortex by 63 % as assessed by TTC staining
[12]. Rats were lethally anesthetized at 12 h of reperfusion,
brains were rapidly removed, and the same dorsolateral
parts of the cerebral cortex containing MCA territory were
dissected. Total RNA was extracted using TRI reagent
(Sigma, Germany) and cleaned using RNeasy Total RNA
kit (Qiagen, Germany). The amount and quality of the RNA
were determined by capillary electrophoresis with the
Bioanalyzer 2100 (Agilent Technologies).
Microarray gene expression profiling
Comparative analysis of global gene expression was per-
formed on two experimental paradigms: LPS-stimulated
primary microglial cultures (six independent cultures for
the control conditions and four RNA samples for LPS-
treated cultures) and brain ischemia induced by middle
cerebral artery occlusion (sham-operated (S) and MCAo-
subjected rats with (F) or without (M) treatment with
FK506, n03).
Biotin-labeled cRNAs were synthesized with the Affy-
metrix IVT labeling kit. Fragmented cRNA was hybridized
first to a control microarray and then, after sample quality
evaluation, was hybridized to the Affymetrix GeneChip Rat
Genome 230-2.0 Gene Chips (31,042 probe sets including
28,000 rat genes).
Microarray data were preprocessed with the MAS 5.0
algorithm, as implemented in the "affy" R Bioconductor
package [15]. Only consistently detected probesets in all
hybridizations for at least one condition in a given experi-
ment (call: Present or Marginal) were mapped to Ensembl
57 gene identifiers (gene_stable_id). For each gene, we
computed a single average intensity profile from the profiles
of all the probesets mapped to it. The resulting average
profile was then log2-transformed and used in statistical
analysis and visualization.
In the MCAo model, we used one-way ANOVA to iden-
tify the genes that changed expression among the three
conditions (S, M, and F). We used unpaired Student’s t test,
with Welch’s approximation for the degrees of freedom, to
identify genes with significantly different mean expression
between the contrasted groups (S vs. M, M vs. F). In the in
vitro experiment, we used paired t test to identify genes with
mean difference in expression, between the control and LPS
for matched microglia preparations, significantly different
from zero. For the false discovery rate (FDR) analysis, the
lists of p values were imported into R statistical environment
(http://www.R-project.org), and the q values [16] were cal-
culated using the R “qvalue” package. To identify functional
Gene Ontology categories associated with the observed
changes in expression, the lists of gene symbols (Ensembl
display_id) of the genes with the respective t test p value<
0.05 were ranked on the difference in log2 expression, either
M minus S, or F minus M, and for LPS microglia minus
control, and analyzed using Rank GOstat [17] with the
default options (Wilcoxon signed rank test, Benjamini false
discovery rate correction for multiple testing).
The datasets from both experiments were submitted to
ArrayExpress, and are available with the following
J Mol Med (2012) 90:1459–1471 1461
accession numbers: E-MEXP-2222 (MCAo) and E-MEXP-
2466 (microglia).
Statistical analysis
In vitro experiments were performed on at least three
independently derived primary microglial cultures, in
triplicates. Statistical analysis was carried out using
one-way analysis of variance (ANOVA) followed by
post hoc Newman–Keuls test with STATISTICA soft-
ware (StatSoft, Tulsa, OK, USA). Statistical significance
was determined at three levels: *p<0.05, **p<0.01, and ***p
<0.001. The results are expressed as the mean±standard devi-
ation (SD) or the mean±standard errors of the mean (SEM) is
indicated.
Results
Immunosuppressants inhibit morphological changes
and motility of activated microglia
In response to LPS, microglia undergo activation, which
includes morphological transformation, increased motili-
ty, phagocytosis, and inflammatory gene expression. We
analyzed an influence of FK506 and CsA on LPS-
induced changes in morphology and behavior of the
rat primary microglial cultures. Untreated microglial
cells have bipolar or rod-shape morphology with few
short processes (3 % of cells with 2,000 μm2 or larger
cell body area), and exposure to LPS for 24 h resulted
in cell body enlargement (62 % of cells with
≥2,000 μm2 cell body area) and amoeboid morphology.
Treatment with immunosuppressants reduced LPS-
induced morphological transformation of microglia by
26 % (in case of 5 μM FK506) or 70 % (5 μM CsA)
(Fig. 1a). The inhibitory effect was more prominent at
higher drug concentrations (10 μM FK506 and CsA,
data not shown).
LPS inhibited microglial cell division in both mixed
astrocyte/microglia cultures and in microglial cultures. To
study if immunosuppressants could affect LPS-induced
growth arrest, we assessed microglial proliferation (by mea-
suring of BrdU incorporation) 24 h after treatment with LPS
alone or with drugs. FK506 and CsA did not interfere with
LPS-induced growth arrest, as shown in Fig. 1b.
Motility of microglial cells was examined with a scratch
assay. The untreated microglial cells exhibit weak motility,
only few cells migrated into the scratch area. Prominent
induction of cell migration was observed in cultures trea-
ted with LPS. Immunosuppressants at concentration of
5 μM completely abolished LPS-induced cell motility
(Fig. 1c).
FK506 and CsA differentially modulate LPS-induced
production of inflammation mediators
We evaluated effects of immunosuppressants on the levels
of IL-1β, NO, and Cox-2 produced by microglia. IL-1β
protein level was assessed by Western blotting and ELISA.
Increase of pro-IL-1β (31 kDa) level was detected in micro-
glial cells 1 h after LPS addition and gradually elevated up
to 12 h posttreatment (Fig. 2a), when the mature form of IL-
1β (17 kDa) was detected. Pretreatment with FK506 re-
duced accumulation of the mature IL-1β in a dose-
dependent manner (Fig. 2b). The results were corroborated
by ELISA. Untreated cells produced 0.24±0.03 ng/mL IL-
1β, while upon activation the cytokine concentration
reached 1.5±0.2 ng/mL (Fig. 2c). Treatment with 20 μM
FK506 decreased LPS-dependent cytokine secretion to
0.44±0.1 ng/mL. In contrast, low doses of CsA had no
effect on IL-1β secretion, while 20 μM CsA strongly
elevated IL-1β secretion up to 8.71±1.98 ng/mL.
The iNOS expression was significantly upregulated in
LPS-activated microglia (Fig. 3a), and accordingly, NO
production increased from 1.43±0.57 μM in untreated
cells up to 22.6±0.82 μM in LPS-stimulated cultures
(15.8-fold induction). Treatment with CsA or FK506
significantly decreased LPS-induced iNOS expression
and NO production (Fig. 3a, b). FK506 was more
potent than CsA and reduced the LPS-induced NO
Fig. 1 FK506 and CsA attenuate LPS-induced transformation of
microglia. a Primary microglial cultures were prepared as described
and kept for 48 h after plating to silence microglia. Morphological
alterations of microglia untreated or exposed to 100 ng/mL LPS alone
or with immunosuppressants (at concentration of 5 μM) for 24 h were
visualized by immunofluorescence. Cells were stained with FITC-
conjugated isolectin B4 (green) to visualize cell morphology followed
by staining with DAPI for nuclei visualization (blue); ×20 objective.
Stained cells with a specified range of size and optical density above
fixed threshold value were automatically recognized and counted. Cell
body area of microglial cells was measured, and the percentage of cells
with body area >2,000 μm2 (activated cells) was calculated. Left panel
shows the histograms representing the distribution of microglial cells
body area (square micrometers) for all analyzed experimental condi-
tions. Data are expressed as means±SD from ten fields for all treat-
ments in three independent experiments. b FK506 and CsA do not
inhibit LPS-induced growth arrest of microglial cells. Microglial pro-
liferation was determined with BrdU incorporation assay 24 h after
treatment. The results are means±SEM of three independent experi-
ments, each in triplicate. c Immunosuppressants affect migration of
activated microglia. Confluent microglial cultures were scratched with
a plastic 100-μL tip, washed with PBS, and incubated for 5 h under
given conditions. Cells migrating to a cell-free area without the treat-
ment, after addition of 100 ng/mL LPS alone or with immunosuppres-
sants (5 μM), were visualized by phase-contrast microscopy
(magnification ×4). Left panel shows quantitative evaluation of motil-
ity/migration of microglia treated with LPS alone or with immunosu-
pressants at 6 h time point. Cells from five fields between scratch edges
along the line were counted. Results represent means±SD from two
independent experiments each in triplicate

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Fig. 2 FK506 reduces LPS-
induced production of IL-1β by
microglial cells. a Kinetics of
LPS-induced production of IL-
1β. Immunoblot shows the
levels of pro-IL-1β (31 kDa)
and mature IL-1β (17 kDa)
protein in extracts from micro-
glial cells at different times after
treatment with 100 ng/mL LPS.
β-Actin detection ensured an
equal protein loading. Similar
results were observed on three
independently derived micro-
glial cultures. b Attenuation of
LPS-induced production of the
mature form of IL-1β in cells
exposed to 5 and 20 μM FK506
for 12 h. c Effects of immuno-
suppressants on IL-1β secretion
by LPS-stimulated microglial
cultures evaluated by ELISA
assay at 12 h after treatment.
Results are expressed as per-
centage of the IL-1β release
obtained in untreated cells;
means±SEM from three
experiments (each in triplicate)
are presented
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production by 58.42 and 66.34 % at the concentration
of 10 and 20 μM, respectively, while CsA treatment
resulted in 44.89 and 45.22 % reduction.
Cox-2 expression strongly upregulated by LPS treatment
(Fig. 3c) was reduced by 5 and 10 μM FK506. In contrast,
5 μM CsA had no effect and at the higher dose increased the
Cox-2 protein expression. Densitometry of immunoblots
from three independent experiments confirmed reduction
of LPS-induced Cox-2 protein expression in FK506- but
not CsA-treated cultures.
Fig. 3 Immunosuppressants affect LPS-induced production of inflam-
matory mediators in rat microglial cultures. a Immunoblot shows that
FK506 and CsA reduce the level of iNOS protein in microglial cells
exposed for 24 h to 100 ng/mL LPS alone or together with FK506 or
CsA (5 or 10 μM). Densitometry of immunoblots from three indepen-
dent experiments was performed. The level of iNOS expression was
normalized to β-actin content. All values are related to untreated
controls and presented as the mean values±SEM. b Nitric oxide
production was determined as nitrite concentration in cell culture
supernatants and expressed as percentage of the release by untreated
cells. Results represent means±SEM obtained from three independent-
ly derived cultures (each in triplicate). c FK506 (but not CsA) reduces
LPS-induced expression of Cox-2 protein in microglial cultures. Den-
sitometry of immunoblots from three independent experiments was
performed. The level of Cox-2 expression was normalized to β-actin
content, related to controls and presented as means±SEM
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Fig. 4 FK506 interferes with signal transduction triggered by LPS in
microglial cultures. Immunoblots show the levels of phosphorylated
forms of MAP kinases (a) their substrates, MAPKAPK2 and c-Jun (b)
and IκB (c) Western blot analyses were performed with total extracts
from microglial cultures treated with LPS alone or with FK506. Similar
results were obtained in four independent experiments. The level of
phosphorylated MAPK was quantified by densitometry, related to the
β-actin level and then to values obtained for untreated microglia.
Results are presented as means±SEM from three independent
experiments
1466 J Mol Med (2012) 90:1459–1471
FK506 affects MAPK signaling in microglia
Three MAPKs were activated shortly after stimulation of
microglial cultures with LPS, as shown by Western blotting
(Fig. 4a). Treatment with 5 and 10 μM FK506 decreased the
levels of LPS-induced phosphorylation of MAPK at 1 and
3 h. Densitometry of immunoblots from four independent
experiments demonstrated reduction of MAPK phosphory-
lation in FK506-treated microglial cultures. Concomitantly,
LPS-triggered phosphorylation of downstream substrates of
p38 and JNK, respectively MAPKAPK-2 and c-Jun, was
also decreased by immunosuppressants (Fig. 4b). Moreover,
pretreatment with FK506 or CsA inhibited LPS-induced
activation of NFκB, a key transcriptional regulator of in-
flammatory response, as assessed by detection of the phos-
phorylated form of IκB (Fig. 4c). Our results indicate that
FK506 impairs activation of MAPK and NFκB signaling in
microglial cells that may result in blockade of inflammatory
responses.
Inflammation-related genes induced in ischemic brain
and LPS-stimulated microglia are blocked by FK506
Since we demonstrated that the expression of crucial inflam-
matory factors such as IL-1β, IL-6, and TNF-α reached its
maximum in the ipsilateral cortex at 12 h of reperfusion
[12], global gene expression profiling in ischemic cortex has
been performed 12 h after MCAo, MCAo followed by
FK506 treatment, or in sham-operated animals, microglial
cells were harvested 6 h of LPS stimulation (100 ng/mL), at
the time point when the expression of inflammation-related
genes was upregulated in vitro [18]. For comparisons of the
sets of genes regulated by the studied treatments, we choose
a uniform p value threshold of 0.05 in order to achieve gene
sets of comparable sizes for each treatment. In the ischemic
cortex, 1,803 genes significantly changed expression, with
the cutoff at p value 0.05, FDR q value 0.15, among the
10,404 reliably detected genes. In LPS-treated microglia,
4,949 genes significantly changed its expression, with the
cutoff at p value 0.05, FDR q value 0.03, among the 9,147
reliably detected genes.
Strong and consistent changes in the expression of sim-
ilar sets of genes were observed in both systems. Analysis of
the ranked list of genes that significantly changed expres-
sion (p<0.05) after MCAo, and—separately—in LPS-
treated microglia, revealed that in both experimental
systems, the most affected genes represent similar Gene
Ontology (GO) categories, including: “immune system
process” and “inflammatory response” (Fig. 5a). Focusing
only on genes that significantly changed expression in both
models revealed 843 such genes (with t test p values of
<0.05 in both datasets).
The top panel of Fig. 5b shows relative changes in gene
expression induced by LPS in microglial cultures, and by
stroke in the ischemic cortex, plotted against each other on
the log2 scale. The log2 changes in gene expression in both
systems were positively correlated (r00.60, df0841, p
value07.2, 10–84). The counts of the genes in each quadrant
of the top panel of Fig. 5b (a contingency table) are given in
Electronic supplementary materials (ESM) Table 3. Given
these data, we asked if induction of a gene by LPS in the
microglia in vitro predicts induction of the same gene in the
cortex following the MCAo. As it turned out, there is a highly
significant association between induction in both systems
(Fisher’s exact test p value01.3, 10–47). When the induction
by LPS was used to predict induction following the MCAo,
for all the genes regulated in both systems, the sensitivity and
specificity of prediction were 68 and 85 %, respectively.
However, when the analysis was performed only for the 33
genes that were regulated in both systems and additionally
assigned to the GO: inflammatory response term, the sensi-
tivity and specificity of the prediction rose to 94 and 100 %,
respectively. Thus, for the inflammatory response genes, upre-
gulation by LPS in microglia in vitro accurately predicts
upregulation following MCAo.
Majority of those genes, namely 615, were regulated in
the same direction in both systems (dots in the I and III
quadrant). Remarkably, 392 genes were upregulated in both
systems (dots in the I-st quadrant). Thus, we identified a set
of 392 genes upregulated in microglial cultures by LPS
treatment that were also upregulated following MCAo. For
those genes, the fold changes of expression were similar in
both systems (dots scattered around the diagonal Y0X), and
many of them were assigned to the GO category “inflam-
matory response” (red dots in Fig. 5b). It is likely that those
genes were expressed in the same cell type, namely
microglia.
FK506 treatment greatly reduced the changes in gene
expression induced by MCAo, in particular for the genes
that were most strongly induced by MCAo (Fig. 5b, com-
pare top and bottom panel). In the FK506-treated animals,
1,173 genes had significantly different expression, at p<
0.05, FDR q value00.28, when compared to their expres-
sion in the control group (MCAo). Interestingly, most genes
induced in ischemic cortex (as compared to sham-operated
animals) were downregulated by FK506 treatment. The
functional GO categories represented among the genes most
strongly downregulated by FK506 were the same as the
categories induced by MCAo and included: “response to
external stimulus,” “response to wounding,” “immune sys-
tem process,” and “inflammatory response” (Fig. 5a). Many
of the genes affected by the FK506 treatment are assigned to
several of these categories (Fig. 5c). Two categories, namely
the “inflammatory response” and “immune system process,”
were also induced by the LPS treatment (Fig. 5a). Validation
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of microarray data by qPCR in independent samples of
differently stimulated microglia (n03) and in vivo experi-
ments (n03–5 rats) is provided in ESM Fig. 2. The expres-
sion of nine genes, representing the most important targets
for FK506 action, chosen on the basis of microarray analy-
sis, has been verified. We confirmed the significant inhibi-
tion of inflammation-related gene expression (ccl20, il6,
cxcl2, ccl3, ccl4, il1β, and stat3) by FK506 treatment
(ESM Fig. 2A). Moreover, we validated the same effect of
FK506 on LPS-stimulated microglia (ESM Fig. 2B). In both
experimental paradigms, FK506 did not significantly affect
bdnf expression, as we have previously reported [12]. The
results achieved are in accordance with our previously dem-
onstrated data that FK506 administered 1 h after transient
MCAo ameliorated brain damage, reduced microglia acti-
vation as well as production of pro-inflammatory cytokine
IL-1β in the ischemic penumbra (representative images of
FK506 neuroprotective and anti-inflammatory effect are
provided in ESM Fig. 3).
Discussion
The main finding of this study is that FK506 restrains acute
inflammatory responses in cultured microglial cells as well
as in the ischemic brain. FK506 reduced LPS-induced acti-
vation of MAPK and NFκB signaling pathways, affecting
crucial steps of microglia activation. This results in inhibi-
tion of morphological transformation, motility, and expres-
sion of inflammation mediators: IL-1β, Cox-2, and iNOS in
inflammatory microglia. CsA applied at similar doses mim-
icked most of FK506 effects but failed to inhibit LPS-
induced IL-1β production and Cox-2 expression. We ob-
served upregulation of IL-1β secretion in cultures treated
with 20 μM CsA, likely reflecting release of cellular content
during CsA-induced cell death as microglial viability was
reduced by concomitant treatment with LPS and 20 μM
CsA (MTT metabolism test, data not shown). Also in naïve
microglia, the mature IL-1β production was upregulated by
20 μM CsA (ESM Fig. 1). Cox-2 and iNOS expression was
barely detectable under basal conditions, and the treatment
of naïve, microglial cells with immunosuppressants did not
affect their expression.
Our findings emphasize that FK506 is an efficient mod-
ulator of inflammatory responses in activated microglia in
vitro and likely in vivo. Gene expression profiling revealed
that FK506 attenuates global upregulation of “injury” and
“inflammation-related” genes in the ischemic brain. Most
significantly affected GO functional categories: “response to
external stimulus,” “response to wounding,” and “inflam-
matory response” could reflect contribution of microglial
expression to global genomic responses. The expression of
a majority of upregulated inflammation-related genes was
almost completely inhibited in FK506-treated ischemic
animals.
Interestingly, FK506 strongly affected production of the
mature IL-1β and cytokine secretion in microglial cultures.
In response to LPS, newly synthesized IL-1β remains most-
ly cell associated and requires proteolytical processing by a
cysteine protease IL-β-converting enzyme (caspase-1) to
generate an active cytokine [19]. Inhibition of externaliza-
tion or/and proteolytic processing of pro-IL-1β in FK506-
treated microglial cultures could be a novel mechanism of
drug action. However, this may not be a primary event, but a
consequence of halting microglia activation. Inhibition of
IL-1β activity or signaling with antibodies neutralizing
cytokines or soluble cytokine receptors decreased neuronal
damage in animal models of stroke [20]. Promising results
of IL-1 receptor antagonist delivered peripherally were ob-
served in stroke patients [5].
We show that LPS-induced upregulation of iNOS expres-
sion and NO production were inhibited strongly by FK506
and less potently by CsA. Previous results on the macro-
phage cell line RAW264.7 [21] or murine J774 macro-
phages suggested that 1–5 μg/mL CsA reduced iNOS
expression and NO production, while FK506 was not [22]
or less effective [23]. Both immunosuppressants inhibited
LPS-induced NO production in rat peritoneal macrophages
[24] that is in agreement with our results. We demonstrate
that FK506 (but not CsA) significantly reduced LPS-
Fig. 5 FK506 blocks upregulation of numerous inflammation-related
genes in the ischemic cortex. a Gene Ontology “biological process”
terms most significantly associated with the changes in gene expres-
sion induced by MCAo in the ischemic cortex, with or without FK506
treatment, and by LPS activation of microglia in vitro. Analysis was
performed on the remote RankGOStat server, with ranked lists of log2
changes in expression of the genes with the respective t test p value<
0.05 used as the input files, and RGD selected as the target database.
For the plot, the FDR-corrected association p values were log10-
transformed and signed, i.e., multiplied by +1 or −1 to reflect associ-
ation with increased or decreased expression, respectively. Numbers of
genes in each GO category are given in parentheses. b Comparison of
log2 changes in gene expression induced in microglia by LPS and after
MCAo for the genes significantly regulated in both systems (top
panel). The changes of the same genes as in the top panel are compared
to the changes induced by MCAo in the animals that received FK506
(bottom panel). Red dots represent gene assigned to GO: inflammatory
response. c. Venn diagram of the genes affected by FK506 treatment
assigned to GO categories: “response to external stimulus,” “response
to wounding,” “immune system process,” and “inflammatory re-
sponse.” A newer local version of the GO database was used than by
the RankGOStat server, resulting in larger numbers of genes assigned
to the same GO terms than in (a). For details of the gene names and the
expression data, see ESM Table 1. d Heat maps of expression profiles
of the genes in GO catagories: “response to wounding” and “inflam-
matory response” that were regulated by FK506. The genes were
sorted on the change in expression induced by MCAo (as compared
to sham). The genes that were also significantly regulated during
microglia activation with LPS are marked with an asterisk

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induced upregulation of Cox-2 protein which corresponds to
the results reporting lack of CsA effect on LPS-induced
Cox-2 expression in human microglial cells [25]. Inhibition
of Cox-2 activity, either genetically or pharmacologically,
had neuroprotective effects in rodent models of stroke,
possibly via suppression of inflammatory reactions [26].
Inhibition of numerous microglial functions by immuno-
suppressants suggests blocking the early steps of microglia
activation. However, the most described mode of FK506
action is inhibition of calcineurin, the inhibitory effects of
other signaling pathways have been described, exemplified
by inhibition of MAPK signaling in lymphocytes. In most
cells, including glial cells, inhibition of calcineurin signaling
is achieved with 1 μMCsA or FK506. As in LPS-stimulated
microglia, the inhibitory effects are observed at ≥5 μM CsA
or FK506; we suggest that inhibition of calcineurin is not a
triggering event and rather inhibition of MAPK signaling,
that is an early event and partly dependent on chaperone
functions of immunophilins, plays more important role.
Here, we demonstrate that FK506 reduced MAPK phos-
phorylation in LPS-treated microglia that may be a potential
mechanism of drug action. MAP kinases mediate microglial
responses to LPS, cytokines, and growth factors, and control
production of inflammatory mediators. MAPK inhibitors act
as anti-inflammatory drugs by reducing synthesis of inflam-
mation mediators at multiple levels and blocking inflam-
matory cytokine signaling [27, 28]. ERK, JNK, and p38
MAP kinases are activated by LPS in microglia and inhi-
bition of a respective kinase with pharmacological inhib-
itors: CEP11004 or CEP-1347 reduced cytokine production
in LPS-stimulated human and murine microglia cultures
[29, 30] or exposed to neurotoxic peptide Aβ1-40 [30].
SP6001, an inhibitor of JNK, reduced LPS-induced Cox-2,
TNF-α, MIP-1, and IL-6 expression, while inhibitors of
ERK1/2 and p38 attenuated LPS-induced cell enlargement
[31]. Our results find confirmation in recent data showing
inhibition of JNK activity in FK506-treated animals that
links the neuroprotective action of FK506 with JNK sig-
naling [32]. The inhibitory effect of FK506 on MAPK
signaling may explain complex action, both on initiation
as well as on propagation of inflammatory responses in
microglia. Small molecule inhibitors’ targeting of p38
MAPK and JNK pathways showed a great potential as
potent modulators of brain inflammation and gliosis in
neurological disorders, where cytokine overproduction con-
tributes to disease progression [27, 28, 33]. Inhibitors of
p38 MAPK and ERK reduced IL-1β production, brain
injury, and neurological deficits in cerebral focal ischemia
[34, 35]. Studies with MAPK inhibitors on microglial
cultures revealed distinct roles of particular kinase in con-
trolling specific events in microglial activation [31], sug-
gesting that a cocktail of MAPK inhibitors would be
required to block efficiently all microglial responses. We
demonstrate that FK506, a well-known drug with good
pharmacokinetics, efficiently blocks many functions of
microglia: cell enlargement, migration, and production of
inflammation mediators at clinically relevant concentra-
tions offering a new opportunity for treatment of poststroke
neuroinflammation.
Competing interests The authors declare that they have no competing
interests.
Sources of funding This study was supported by grants NN401
0475 and PBZ/MEiN/01/2006/32 from the Polish Ministry of Science
and Higher Education and PERG05-GA-2009-240705 from the FP7-
PEOPLE-2009-RG.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. Hanisch UK, Kettenmann H (2007) Microglia: active sensor and
versatile effector cells in the normal and pathologic brain. Nat
Neurosci 10:1387–1394
2. Aloisi F (2001) Immune function of microglia. Glia 36:165–179
3. Allan SM, Tyrrell PJ, Rothwell NJ (2005) Interleukin-1 and neu-
ronal injury. Nat Rev Immunol 5:629–640
4. Loddick SA, Rothwell NJ (1999) Mechanisms of tumor necrosis
factor alpha action on neurodegeneration: interaction with insulin-
like growth factor-1. Proc Natl Acad Sci U S A 96:9449–9451
5. Simi A, Tsakiri N, Wang P, Rothwell NJ (2007) Interleukin-1 and
inflammatory neurodegeneration. Biochem Soc Trans 35:1122–1126
6. Kaminska B, Gaweda-Walerych K, Zawadzka M (2004) Molecular
mechanisms of neuroprotective action of immunosuppressants—
facts and hypotheses. J Cell Mol Med 8:45–58
7. Gold BG, Villafranca JE (2003) Neuroimmunophilin ligands: the
development of novel neuroregenerative/neuroprotective com-
pounds. Curr Top Med Chem 3:1368–1375
8. Macleod MR, O’Collins T, Horkey LL, Howells DW, Donnan GA
(2005) Systematic review and metaanalysis of the efficacy of FK506
in experimental stroke. J Cereb Blood Flow Metab 25:713–721
9. Furuichi Y, Maeda M, Matsuoka N, Mutoh S, Yanagihara T (2007)
Therapeutic time window of tacrolimus (FK506) in a nonhuman
primate stroke model: comparison with tissue plasminogen activa-
tor. Exp Neurol 204:138–146
10. Furuichi Y, Noto T, Li JY, Oku T, Ishiye M, Moriguchi A, Aramori
I, Matsuoka N, Mutoh S, Yanagihara T (2004) Multiple modes of
action of tacrolimus (FK506) for neuroprotective action on ische-
mic damage after transient focal cerebral ischemia in rats. Brain
Res 1014:120–130
11. Tsujikawa A, Ogura Y, Hiroshiba N, Miyamoto K, Kiryu J, Honda
Y (1998) Tacrolimus (FK506) attenuates leukocyte accumulation
after transient retinal ischemia. Stroke 29:1431–1437
12. Zawadzka M, Kaminska B (2005) A novel mechanism of FK506-
mediated neuroprotection: downregulation of cytokine expression
in glial cells. Glia 49:36–51
13. Szydlowska K, Gozdz A, Dabrowski M, Zawadzka M, Kaminska
B (2010) Prolonged activation of ERK triggers glutamate-induced
1470 J Mol Med (2012) 90:1459–1471
apoptosis of astrocytes: neuroprotective effect of FK506. J Neuro-
chem 113:904–918
14. Zawadzka M, Kaminska B (2003) Immunosuppressant FK506
affects multiple signaling pathways and modulates gene expression
in astrocytes. Mol Cell Neurosci 22:202–209
15. Irizarry R, Gautier RL, Cope L (2002) An R package for analyses
of affymetrix oligonucleotide arrays. In: The analysis of gene
expression data: methods and software. Springer, New York
16. Storey JD, Tibshirani R (2003) Statistical significance for genome-
wide studies. Proc Natl Acad Sci U S A 100:9440–9445
17. Beissbarth T, Speed TP (2004) GOstat: find statistically overrep-
resented Gene Ontologies within a group of genes. Bioinformatics
20:1464–1465
18. Kaminska B, Gozdz A, Zawadzka M, Ellert-Miklaszewska A, Lipko
M (2009) MAPK signal transduction underlying brain inflammation
and gliosis as therapeutic target. Anat Rec 292:1902–1913
19. Beuscher HU, Gunther C, Rollinghoff M (1990) IL-1β is secreted
by activated murine macrophages as biologically inactive precur-
sor. J Immunol 144:2179–2183
20. Denes A, Pinteaux E, Rothwell NJ, Allan SM (2011) Interleukin-1
and stroke: biomarker, harbinger of damage, and therapeutic target.
Cerebrovasc Dis 32:517–527
21. Attur MG, Patel R, Thakker G, Vyas P, Levartovsky D, Patel P, Naqvi
S, Raza R, Patel K, Abramson D et al (2000) Differential anti-
inflammatory effects of immunosuppressive drugs: cyclosporin, rapa-
mycin and FK-506 on inducible nitric oxide synthase, nitric oxide,
cyclooxygenase-2 and PGE2 production. Inflamm Res 49:20–26
22. Dusting GJ, Akita K, Hickey H, Smith M, Gurevich V (1999)
Cyclosporin A and tacrolimus (FK506) suppress expression of
inducible nitric oxide synthase in vitro by different mechanisms.
Br J Pharmacol 128:337–344
23. Hamalainen M, Lahti A, Moilanen E (2002) Calcineurin inhibitors,
cyclosporin A and tacrolimus inhibit expression of inducible nitric
oxide synthase in colon epithelial and macrophage cell lines. Eur J
Pharmacol 448:239–244
24. Strestikova P, Otova B, Filipec M, Masek K, Farghali H (2001)
Different mechanisms in inhibition of rat macrophage nitric oxide
synthase expression by FK 506 and cyclosporin A. Immunophar-
macol Immunotoxicol 23:67–74
25. Choi HB, Khoo C, Ryu JK, van Breemen E, Kim SU, McLarnon JG
(2002) Inhibition of lipopolysaccharide-induced cyclooxygenase-2,
tumor necrosis factor-alpha and [Ca2+]i responses in human micro-
glia by the peripheral benzodiazepine receptor ligand PK11195. J
Neurochem 83:546–555
26. Minghetti L (2004) Cyclooxygenase-2 (COX-2) in inflammatory
and degenerative brain diseases. J Neuropathol Exp Neurol
63:901–910
27. Kumar S, Boehm J, Lee JC (2003) p38 MAP kinases: key signal-
ling molecules as therapeutic targets for inflammatory diseases.
Nat Rev Drug Discov 2:717–726
28. Kaminska B (2005) MAPK signalling pathways as molecular
targets for anti-inflammatory therapy—from molecular mecha-
nisms to therapeutic benefits. Biochim Biophys Acta Proteomics
1754:253–262
29. Hidding U, Mielke K, Waetzig V, Brecht S, Hanisch U, Behrens A,
Wagner E, Herdegen T (2002) The c-Jun N-terminal kinases in
cerebral microglia: immunological functions in the brain. Biochem
Pharmacol 64:781–788
30. Lund S, Porzgen P, Mortensen AL, Hasseldam H, Bozyczko-
Coyne D, Morath S, Hartung T, Bianchi M, Ghezzi P, Bsibsi M
et al (2005) Inhibition of microglial inflammation by the MLK
inhibitor CEP-1347. J Neurochem 92:1439–1451
31. Waetzig V, Czeloth K, Hidding U, Mielke K, Kanzow M, Brecht S,
Goetz M, Lucius R, Herdegen T, Hanisch UK (2005) c-Jun N-
terminal kinases (JNKs) mediate pro-inflammatory actions of
microglia. Glia 50:235–246
32. Brecht S,WaetzigV, HiddingU, Hanisch UK,WaltherM, Herdegen T,
Neiss WF (2009) FK506 protects against various immune responses
and secondary degeneration following cerebral ischemia. Anat Rec
292:1993–2001
33. Kaminska B, Swiatek-Machado K (2008) Targeting signaling
pathways with small molecules to treat autoimmune disorders.
Expert Rev Clin Immunolog 4:93–112
34. Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S,
Badger AM, White RF, McVey MJ, Legos JJ et al (2001) SB
239063, a second-generation p38 mitogen-activated protein kinase
inhibitor, reduces brain injury and neurological deficits in cerebral
focal ischemia. J Pharmacol Exp Ther 296:312–321
35. Piao CS, Kim JB, Han PL, Lee JK (2003) Administration of the
p38 MAPK inhibitor SB203580 affords brain protection with a
wide therapeutic window against focal ischemic insult. J Neurosci
Res 73:537–544
J Mol Med (2012) 90:1459–1471 1471
